Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three active pharmaceutical ingredients: - **Hydroxychloroquine** is an antimalarial and disease-modifying anti-rheumatic drug (DMARD) used for malaria, rheumatoid arthritis, and lupus erythematosus. It acts by modulating immune system activity and interfering with lysosomal activity in antigen-presenting cells[1][6]. - **Magnesium sulfate** is an inorganic salt used as an electrolyte replenisher in hypomagnesemia, as a tocolytic agent, anticonvulsant in eclampsia, and for other indications. It works primarily by replacing magnesium ions in the body. - **Prednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It acts as an agonist at the glucocorticoid receptor to inhibit pro-inflammatory signals[5]. There are no widely recognized brand or trade names for this specific triple combination; it would be considered an off-label or compounded therapy if prescribed together.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxychloroquine + magnesium sulfate + prednisolone.